Eledon Pharmaceuticals, Inc.
ELDN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001404281
No open-market purchases or sales by Eledon Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $184.9M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +42 vs. previous quarter
- 161
- 13F valueReported value at the end of Q2 2026
- $184.9M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ELDN, Q2 2026
No superinvestor reported holding ELDN at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Eledon Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 31, 2024 (view filing)5:52 PM ET | Oct 29 | 2 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | PPurchaseCommon Stock, $0.001 par value | +4.75M | $3.65 | +$17.3M | –838.5K after | Derivative3 lots |
| May 13, 2024 (view filing)5:04 PM ET | May 9 | 4 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | PPurchaseCommon Stock, $0.001 par value | +1.93M | – | – | New position220.5K after | 3 lots |
| May 13, 2024 (view filing)5:04 PM ET | May 9 | 4 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | PPurchaseCommon Stock, $0.001 par value | +5.93M | – | – | –232.1K after | Derivative3 lots |
| May 9, 2023 (view filing)8:25 PM ET | May 5 | 4 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | PPurchaseCommon Stock, $0.001 par value | +1.98M | – | – | New position145.0K after | 3 lots |
| May 9, 2023 (view filing)8:25 PM ET | May 5 | 4 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | PPurchaseCommon Stock, $0.001 par value | +9.59M | – | – | –252.3K after | Derivative6 lots |
| Nov 23, 2022 (view filing) | Nov 23 | Same day | Perrin StevenPresident | PPurchase | +1.00K | $2.60 | +$2.60K | New position1.00K after | |
| Dec 21, 2021 (view filing) | Dec 20 | 1 day | Gros David-Alexandre CChief Executive Officer | PPurchase | +2.00K | $4.48 | +$8.96K | +28.6%9.00K after | |
| Aug 19, 2021 (view filing) | Aug 17 | 2 days | Gros David-Alexandre CChief Executive Officer | PPurchase | +4.00K | $6.21 | +$24.8K | +133.3%7.00K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Eledon Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BVF Inc | 6,293,282 | $24.8M | 0.63% | 00.0% | Unchanged |
| BlackRock, Inc. | 5,123,842 | $20.2M | 0.00% | +741,597+16.9% | Added |
| Defilade Capital Management, L.P. | 3,525,338 | $13.9M | 1.86% | −38,789−1.1% | Reduced |
| Vanguard Capital Management LLC | 3,417,223 | $13.5M | 0.00% | +124,089+3.8% | Added |
| Goldman Sachs Group Inc | 2,510,308 | $9.89M | 0.00% | +2,140,218+578.3% | Added |
| Ensign Peak Advisors, Inc | 2,101,224 | $8.28M | 0.01% | −363,695−14.8% | Reduced |
| Geode Capital Management, LLC | 1,956,601 | $7.71M | 0.00% | +164,818+9.2% | Added |
| Catalio Capital Management, LP | 1,695,071 | $6.68M | 1.26% | +55,255+3.4% | Added |
| State Street Corp | 1,621,969 | $6.39M | 0.00% | +467,298+40.5% | Added |
| Zimmer Partners, LP | 1,596,599 | $6.29M | 0.15% | −278,401−14.8% | Reduced |